Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.

Levin YD, White RJ.

Drugs Today (Barc). 2011 Feb;47(2):145-56. doi: 10.1358/dot.2011.47.2.1544337. Review.

PMID:
21431102
2.

Tadalafil for the treatment of pulmonary arterial hypertension.

Klinger JR.

Expert Rev Respir Med. 2011 Jun;5(3):315-28. doi: 10.1586/ers.11.38. Review.

PMID:
21702653
3.

Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.

Frantz RP, Durst L, Burger CD, Oudiz RJ, Bourge RC, Franco V, Waxman AB, McDevitt S, Walker S.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):550-7. doi: 10.1177/1074248414528066. Epub 2014 Apr 17.

PMID:
24742768
4.

Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.

Lichtblau M, Harzheim D, Ehlken N, Marra A, Pinado FP, Grünig E, Egenlauf B.

Lung. 2015 Feb;193(1):105-12. doi: 10.1007/s00408-014-9657-7. Epub 2014 Oct 16.

PMID:
25318865
5.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
6.

Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.

Arif SA, Poon H.

Clin Ther. 2011 Aug;33(8):993-1004. doi: 10.1016/j.clinthera.2011.06.008. Epub 2011 Jul 16. Review.

PMID:
21762988
7.

Initial experience with tadalafil in pediatric pulmonary arterial hypertension.

Takatsuki S, Calderbank M, Ivy DD.

Pediatr Cardiol. 2012 Jun;33(5):683-8. doi: 10.1007/s00246-012-0180-4. Epub 2012 Mar 9.

8.

Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.

Sabri MR, Beheshtian E.

Pediatr Cardiol. 2014 Apr;35(4):699-704. doi: 10.1007/s00246-013-0840-z. Epub 2013 Nov 20.

PMID:
24253611
9.

Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.

Shapiro S, Traiger G, Hill W, Zhang L, Doran AK.

Cardiovasc Ther. 2013 Oct;31(5):274-9. doi: 10.1111/1755-5922.12038.

PMID:
23841794
10.

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

Falk JA, Philip KJ, Schwarz ER.

Vasc Health Risk Manag. 2010 May 6;6:273-80. Review.

11.
12.

Tadalafil for the treatment of pulmonary arterial hypertension.

Rosenzweig EB.

Expert Opin Pharmacother. 2010 Jan;11(1):127-32. doi: 10.1517/14656560903413542. Review.

PMID:
20001434
13.

Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.

Shlobin OA, Brown AW, Weir N, Ahmad S, Lemma M, Nathan SD.

Lung. 2012 Oct;190(5):573-8. Epub 2012 Jul 15.

PMID:
22797830
14.

Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.

Palma G, Giordano R, Russolillo V, Cioffi S, Palumbo S, Mucerino M, Poli V, Vosa C.

Tex Heart Inst J. 2011;38(3):238-42.

15.

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.

Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ; PHIRST Study Group.

J Am Coll Cardiol. 2012 Aug 21;60(8):768-74. doi: 10.1016/j.jacc.2012.05.004. Epub 2012 Jul 18.

16.

[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].

Kiliçkesmez K, Küçükoğlu MS.

Anadolu Kardiyol Derg. 2010 Sep;10 Suppl 2:16-8. doi: 10.5152/akd.2010.125. Review. Turkish.

17.

Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.

Chaumais MC, Perrin S, Sitbon O, Simonneau G, Humbert M, Montani D.

Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1193-205. doi: 10.1517/17425255.2013.804063. Epub 2013 Jun 12. Review.

PMID:
23944387
18.

Sildenafil: a review of its use in pulmonary arterial hypertension.

Croom KF, Curran MP.

Drugs. 2008;68(3):383-97. Review.

PMID:
18257613
19.

Tadalafil for the treatment of pulmonary arterial hypertension.

Frey MK, Lang I.

Expert Opin Pharmacother. 2012 Apr;13(5):747-55. doi: 10.1517/14656566.2012.662220. Epub 2012 Feb 23. Review.

PMID:
22356534
20.

Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F.

J Am Coll Cardiol. 2004 Oct 6;44(7):1488-96.

Supplemental Content

Support Center